<h1>Cabinet Approves $750M FDI in Mylan Labs for Jai Pharma Acquisition; Sets Conditions on Production and R&D.</h1> The Union Cabinet, chaired by the Prime Minister, approved a proposal for increasing Foreign Direct Investment (FDI) up to $750 million in Mylan Laboratories Limited by Mylan Luxembourg S.a.r.l. and/or Mylan Group B.V. This investment will fund the acquisition of Jai Pharma Ltd. shares post-demerger. Conditions include maintaining production levels of consumables and NLEM drugs, R&D expenses, and technology transfer information for five years. No non-compete clauses are allowed. Tax implications, including capital gains and dividend taxation, will be assessed independently by tax authorities, with no immunity from investigations or automatic tax relief eligibility.